The risk of pancreatitis with sitagliptin use in routine care remains to be established in older patients. We aimed to determine this risk in older adults who were newly prescribed sitagliptin versus an alternative hypoglycemic agent in the outpatient setting.
S
itagliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, reduces blood glucose by decreasing glucagon secretion and blocking the breakdown of glucagon-like peptide-1, an incretin hormone that stimulates insulin secretion in a glucose-dependent fashion. 1 Sitagliptin was the first DPP-4 inhibitor approved on the Ontario's general benefits formulary in June of 2010. Because of its relative potency (it decreases glycosylated hemoglobin by up to 1% as monotherapy) and low risk of hypoglycemia, 2 sitagliptin use has increased substantially over recent years (more than 700 000 prescriptions in Ontario from June 2010 to June 2012). 3 Despite its benefits, sitagliptin has been linked with pancreatitis in case reports, animal studies and postmarketing drug surveillance studies. [4] [5] [6] [7] It has been postulated that incretin drugs (including DPP-4 inhibitors and glucagon-like peptide-1 agonists) might promote pancreatitis by increasing pancreatic mass, modifying enzyme secretion, disturbing acinar architecture, promoting inflammation, or increasing ductal turnover and metaplasia. 6, 8 As pancreatitis can lead to morbidity and mortality, warnings of the association have been published by regulatory agencies, pharmaceutical companies and diabetes association guidelines (Appendix 1, available at www.cmajopen.ca/content/3/2/E172/suppl/DC1).
The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study
In real-practice observational studies, however, the link between DPP-4 inhibitors and pancreatitis has been inconsistently described, and studies have been limited in their collection of baseline covariates, drug use and health care use. 5, 7, 9 Studies have also used self-reported outcomes, 7, 9, 10 and have been limited to younger populations, making results less generalizable to older adults. 5, 11 We thus aimed to examine the risk of acute pancreatitis with sitagliptin therapy in routine care in a large, representative population of older adults.
Methods

Study design and setting
We conducted a population-based retrospective cohort study involving adults aged 66 years and older from June 2010 to December 2012 using linked (via unique, encoded identifiers) health care databases in Ontario, Canada. Ontario has about 1.8 million adults aged 65 years and older who have comprehensive universal health care. This includes coverage for outpatient prescription medications, physician services, hospital admissions and diagnostic tests. 12 This study was conducted at the Institute for Clinical Evaluative Sciences according to a prespecified protocol that was approved by the research ethics board at Sunnybrook Health Sciences Centre (Toronto, Canada). Informed consent was not required. Our report follows guidelines for the description of observational studies. 13 
Data sources
We obtained patient characteristics, drug use, covariate information and outcome data using records from 6 databases. Vital statistics were obtained from the Registered Persons Database of Ontario, which holds demographic information on all residents who have been issued a health card. The Ontario Drug Benefit Program database contains accurate records of all drug formulary medications dispensed to those aged 65 years and older, with an error rate of less than 1%.
14 Diagnostic and procedural information on hospital admissions and emergency department visits was abstracted from the Canadian Institute for Health Information's Discharge Abstract Database and the National Ambulatory Care Reporting System database, respectively. Covariate information was derived from the Ontario Health Insurance Plan database, which includes health claims for inpatient and outpatient physician services. We used the Institute for Clinical Evaluative Sciences Physician Database to determine prescriber information. Previous studies have used these databases to research adverse drug events and outcomes. [15] [16] [17] [18] [19] A subpopulation in southwestern Ontario had outpatient glycosylated hemoglobin measurements available before a new hypoglycemic agent prescription. 20 With the exception of prescriber information (missing in about 9.6%) and income quintile (missing in about 0.4%), databases were complete for all variables used. International Statistical Classification of Diseases and Related Health Problems, 10th revision (post-2002) and Canadian Classification of Health Interventions (post-2002) codes were used to assess baseline comorbidities and investigations in the 5 years before the hypoglycemic agent prescription (Appendix 2, available at www.cmajopen.ca/content/3/2/E172/suppl/DC1). Codes used to assess the outcome of acute pancreatitis are detailed in Appendix 3 (available at www.cmajopen.ca/content/3/2/E172/ suppl/DC1).
Patient selection
To mimic routine practice, we studied older adults newly prescribed sitagliptin or an alternative hypoglycemic agent (metformin, glyburide, gliclazide or insulin) between June 2010 (when sitagliptin was first openly listed on the province's formulary) and December 2012. The date of the new hypoglycemic drug prescription served as the index date (cohort entry date or start time for follow-up).
In the sitagliptin group we excluded the following patients: those in their first year of eligibility for prescription drug coverage (aged 65 yr) to avoid incomplete medication records; those with a hospital discharge in the 2 days before or on the index date to ensure these were new sitagliptin prescriptions (in Ontario, patients continuing a medication initiated in hospital typically have their medication dispensed on the same day or the day after discharge); those with a code for anesthesia or an epidural in the 30 days before the index date to exclude those with a recent surgery, a risk factor for pancreatitis; those with evidence of a pancreas transplant or pancreatectomy in the 5 years before the index date, to exclude those with surgical manipulation of the pancreas; those with a prescription for 1 or more DPP-4 inhibitors in the 1 year prior (to define new use); and those prescribed saxagliptin or a sitagliptin-metformin combination pill (to restrict to sitagliptin use only).
In patients prescribed an alternate hypoglycemic agent, we applied similar exclusion criteria with differences as follows. We excluded those initiated on metformin without evidence of a code for diabetes in the Ontario Diabetes Database, 21 because diabetes itself is a risk factor for pancreatitis, and metformin can be prescribed for indications other than diabetes; 5, 7 those with a prescription for the same hypoglycemic agent in the 1 year prior (to define new use); those with a prescription for a DPP-4 inhibitor in the 1 year prior (to compare mutually exclusive groups); and those who were previously entered in the sitagliptin cohort. A patient could enter the cohort only once.
Exposure
For the primary analysis, we used an "intention to treat" exposure definition. Following a new hypoglycemic agent prescription, patients were followed until they experienced the primary outcome (defined below), reached 90 days of follow-up or died.
Outcomes
The primary outcome was a hospital encounter (emergency department visit or hospital admission) with acute pancreatitis within 90 days of the index date. We chose 90 days of follow-up to avoid crossover in drug therapy that could occur with longer periods of follow-up, because prescriptions covered by Ontario's drug plan are prescribed at no more than 100-day intervals, and because previous reports have suggested that patients may be at risk for pancreatitis within this time frame of study. 6, 11, 22 Research CMAJ OPEN
Statistical analysis
We used standardized differences to compare baseline characteristics between groups. This metric describes differences between group means relative to the pooled standard deviation and is considered meaningful if greater than 10%. 23 The propensity score was derived from a logistic regression model with 29 baseline covariates incorporated into the score based on prior recommended methods (Appendix 4, available at www.cmajopen.ca/content/3/2/E172/suppl/DC1). 24 Inverse probability of treatment weights were calculated using the propensity model to create a sample in which the distribution of measured baseline covariates was independent of treatment assignment. 24 For the reference group, we considered those prescribed an alternative hypoglycemic agent. We expressed the risk of acute pancreatitis in relative and absolute terms. To calculate odds ratios (ORs) and 95% confidence intervals (CIs), we fit a logistic regression model using a robust variance estimate, accounting for inverse probability of treatment weights.
We conducted all analyses with SAS version 9.3 including analyses we undertook after knowledge of the primary results. We interpreted 2-tailed p values less than 0.05 as significant.
Sensitivity analyses
In time-to-event analysis we extended follow-up beyond 90 days, terminating the observation period for reasons of death, discontinuation of the study hypoglycemic agent, receipt of a nonstudy hypoglycemic agent or the last date of available records (Mar. 31, 2013). We also restricted our cohort to patients accrued after June 2011 to address the possibility of incomplete DPP-4 inhibitor records before June 2010, because sitagliptin became available on the general access formulary in June 2010. Differences in diagnostic testing between groups were evaluated over the course of follow-up by investigating the proportion of patients with amylase and lipase tests. Finally, we examined separately the risk of pancreatitis in patients taking metformin, sulfonylurea and insulin, and in those where the relevant hypoglycemic agent was prescribed as monotherapy or in the setting of another hypoglycemic agent or agents.
Results
Baseline characteristics
Patient selection is presented in Figures 1 and 2 . There were 57 689 patients newly prescribed sitagliptin and 83 405 patients newly prescribed an alternative hypoglycemic agent over the course of study. Before weighting, patients given sitagliptin were younger and taking more medications, and in the years prior, had fewer hospital visits and more diagnostic testing than patients given alternative hypoglycemic agents. After weighting, there were 57 689 in the sitagliptin group and 55 
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705 in the alternative hypoglycemic agent group, and characteristics were similar between the groups (standardized difference less than 10%). Baseline characteristics are outlined in Tables 1-3 and Appendix 5 (available at www.cmajopen.ca/ content/3/2/E172/suppl/DC1). Beyond the index prescription, 84.7% and 76.1% of patients given sitagliptin and alternative hypoglycemic agents, respectively, filled at least 1 additional prescription for the relevant hypoglycemic agent. The duration of continuous study drug use (defined by the duration of 1 prescription overlapping with a subsequent prescription, allowing for a 10-day grace period between prescriptions), was about 81, 64, 91, 82 and 108 days in the sitagliptin, insulin, glyburide, gliclazide and metformin groups, respectively.
Outcomes
Results for the primary outcome of pancreatitis are presented in Table 4 . Sitagliptin use was not associated with a higher 90-day risk of a hospital encounter with pancreatitis than alternative hypoglycemic agent use (weighted total 46 of 57 
Sensitivity analyses
Our findings remained robust in sensitivity analyses. Results of the time to event analysis are shown in Table 5 . Sitagliptin use was not associated with a higher risk of a hospital encounter 
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Interpretation
In our cohort, the initiation of sitagliptin was not associated with a higher 90-day risk of a hospital encounter with acute pancreatitis than the initiation of metformin, glyburide, gliclazide or insulin in routine care. The findings of our study are consistent with the results of randomized controlled trials. A recent systematic review and meta-analysis of 55 randomized trials (33 350 patients) found no difference in the risk of pancreatitis between patients prescribed incretin drugs versus patients prescribed a placebo, lifestyle or other oral hypoglycemic agents (OR 1.11, 95% CI 0.57 to 2.17). 27 A cardiovascular study of patients randomly assigned to saxagliptin or placebo found that rates of acute pancreatitis were similar in both groups (22 †All patients identified before weighting were included in the analyses. The number of patients indicated represents a weighted total. ‡Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by the pooled standard deviation; a value greater than 10% is interpreted as a meaningful difference between the groups. §Baseline medication use was assessed in the previous 120 days. There were no prescriptions for pentamidine, flucytosine, clomiphene, clozapine, acarbose, acetohexamide, chlorpropamide, glimepiride, nateglinide or tolbutamide. There were less than 1% prescriptions for dapsone, isoniazid, procainamide, methimazole and nelfinavir. ¶Hypoglycemic agent use in the previous 120 days includes hypoglycemic drugs prescribed from -120 to -1 day before the index date where days' supply covered the index date. **Hypoglycemic agent use on the index date refers to hypoglycemic drugs prescribed on the same day as study drug (index date).
† †Hypoglycemic agent use in the previous 365 to 120 days includes those hypoglycemic drugs prescribed from -365 to -120 days before the index date. ‡ ‡Numbers less than 6 were not reported for privacy reasons.
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Our results are also consistent with previous observational studies. In a cohort study of 16 276 patients given sitagliptin and 16 281 matched patients given metformin or glyburide, the risk of acute pancreatitis was similar (relative risk 1.0, 95% CI 0.5 to 2.0). 29 An additional cohort study noted comparable rates of pancreatitis in patients taking sitagliptin and alternative hypoglycemic agents (adjusted HR 1.0, 95% CI 0.7 to 1.3), 5 as did a recent report of 20 748 patients taking incretin drugs and 51 712 patients taking sulfonylureas (adjusted HR 1.00, 95% CI 0.59 to 1.70). 30 Further, a study of 1003 cases and 4012 matched controls found that use of incretin drugs in the 6 months prior was not associated with pancreatitis (OR 0.98, 95% CI 0.69 to 1.38). 31 Similar results were noted in a recent Chinese case-control study.
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Our results, however, differ from those of published studies that report a higher risk of pancreatitis with use of DPP-4 inhibitors. Studies using the US Food and Drug Administration database have found that patients taking incretin drugs had a higher odds of pancreatitis (OR 6.74, 95% CI 4.61 to 10.00) than patients taking other oral agents, 7 and that the odds of pancreatitis in patients taking DPP-4 inhibitors was 20.8 times (95% CI 12.6 to 34.5) the odds of pancreatitis in those taking other hypoglycemic agents. 10 A French surveillance study also noted that the rate of exposure to DPP-4 inhibitors was higher in cases of pancreatitis versus non-cases of pancreatitis (67 patients taking DPP-4 inhibitors in 147 cases of pancreatitis v. 421 patients taking DPP-4 inhibitors in 2962 non-cases of pancreatitis, adjusted reporting OR 12.1, 95% CI 7.3 to 20.0). 9 These studies, however, may have been subject to reporting bias as events were self-reported and may have been inflated by external factors. 7, 9 An additional case-control study found that the adjusted odds of acute pancreatitis in those who currently (within 30 d) (OR 2.24, 95% CI 1.36 to 3.68) and who had recently used incretin drugs (past 30 d and less than 2 yr) was higher (OR 2.01, 95% CI 1.37 to 3.18) than in those who had not used incretin drugs. 11 This study performed a more limited assessment of baseline covariates and indices of health care use, and, because it was completed in a younger population (mean age 52 yr), may not be fully generalizable to older adults.
Strengths and limitations
Our study has several strengths. Using a large sample of older patients who used sitagliptin in a routine setting (with multiple comorbidities and taking multiple medications), our study complements information from randomized clinical trials by studying an uncommon but important adverse drug reaction. Our study has adequate statistical power, and the results are generalizable to the larger population. Our newuser design allowed us to observe outcomes after the initiation of treatment. Whereas previous studies included self-reported pancreatitis, in our study pancreatitis was documented in hospital records by the treating health care team. Additionally, to echo routine care and make our findings interpretable in clinical practice, we studied patients who were newly prescribed hypoglycemic alternatives to sitagliptin (metformin, a sulfonylurea or insulin) as a comparison group. We also carried out numerous sensitivity analyses and our primary results remained robust.
Our study has some limitations. Prospective data collection with independent outcome adjudication is a preferred methodology to a retrospective database study. We were unable to detect asymptomatic pancreatitis or pancreatitis that did not result in a hospital presentation. We accurately ascertained medications dispensed but had no information on medication use (although we note that most patients filled at least 1 additional prescription for the relevant study drug).
Given the low event rate of pancreatitis in both groups, we were able to rule out a greater than 1.6-fold increase in the risk of pancreatitis in patients newly prescribed sitagliptin compared with patients newly prescribed alternative hypoglycemic agents with adequate statistical power (upper bound of the CI), but could not rule out a smaller increase in risk. The limited number of events also precluded meaningful subgroup analysis.
The duration of our study did not allow us to measure the long-term effects of sitagliptin. However, we feel that our 90 days follow-up period was reasonable given that the mean duration of continuous drug use ranged from 64 to 108 days, previous reports have suggested that pancreatitis can manifest early in the course of drug exposure, 6, 11, 22 and studies to date have not noted that the risk of pancreatitis differs by exposure duration. 
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The potential for confounding and bias warrants attention. In the current study, we had limited information on factors such as obesity, body mass index and smoking status, which are known to influence the risk of pancreatitis. It is also possible that physicians may have selectively prescribed sitagliptin therapy to healthier people and may have differentially monitored patients for outcomes. However, using propensity score weighting, we obtained good balance on a large number of measured baseline characteristics between the 2 groups. Further, we note that diagnostic testing for pancreatitis was similar among the 2 groups during follow-up.
Conclusion
In older adults, the initiation of sitagliptin did not result in a higher risk of a hospital encounter with pancreatitis than initiation of an alternative diabetic medication (any of metformin, glyburide, gliclazide or insulin). These findings are reassuring for those who use or prescribe sitagliptin in the management of type 2 diabetes. 
